
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
NMPA grants approval for first-line use in combination with chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression BASEL, Switzerland & BEIJING […]













